Takeda Hemophilia A treatment portfolio

ASSOCIATE CREATIVE DIRECTOR, WRITER

Three generations of recombinant Factor Eight (written rFVIII or F8) treatments offer advances in caring for Hemophilia A patients. This brochure presents a comparison, showing users of the older, still-effective products what improvements they could see in their care and quality of life if they changed to a newer product from the same trusted company. The biggest challenge: organizing the complex content into a strong user experience. (MedReg loved it…)